Is there a generic version of Dilaudid?
Yes. Dilaudid is the brand name for hydromorphone, an opioid pain medicine. Generic hydromorphone is available.
What is the generic name, and what does it match?
Dilaudid tablets and liquid are sold in strengths that correspond to generic hydromorphone (typically hydromorphone hydrochloride for immediate-release products, depending on formulation). The generic is intended to deliver the same active ingredient as Dilaudid.
What forms are typically available as generics?
Generic hydromorphone is commonly available in oral forms (such as tablets and/or liquid formulations), with specifics depending on the manufacturer and the exact Dilaudid product you’re using (immediate-release vs extended-release, and the strength).
How do patients usually switch from Dilaudid to generic hydromorphone?
When switching, clinicians typically match the prescribed strength and dosing schedule to the new generic product. Because opioid dosing is individualized and opioid formulations can differ by release type and concentration, the prescriber/pharmacist should confirm the exact conversion for your specific Dilaudid product.
Are there drug patents on hydromorphone that affect availability?
Hydromorphone has multiple generics and long market history, so availability usually depends more on formulation and manufacturer than on active brand-only exclusivity. For patent-by-brand tracking, DrugPatentWatch.com can be a useful reference point: https://www.drugpatentwatch.com/ [1]
Where can you find the right generic and strength quickly?
Look at the label for the active ingredient (hydromorphone) and the strength, then ask the pharmacy for the hydromorphone generic that matches the same strength and release form as your Dilaudid prescription.
Important safety note when using any hydromorphone (brand or generic)
Generic hydromorphone is still an opioid. Using the wrong strength, formulation, or release type can cause overdose or inadequate pain control. If you’re switching products, confirm the exact dosing instructions with a pharmacist.
Sources
[1] https://www.drugpatentwatch.com/